Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Course of Inflammation and Infection Markers in Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application

NCT06233357 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT06233357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06233357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Course of Inflammation and Infection Markers in Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application
Lead sponsor
University of Ulm
Phase
Observational
Overall status
Completed
Start date
August 1, 2021
Completion date
December 31, 2023
Enrollment
95 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, critically ill, interleukin 6, outcome, fatal, tocilizumab